Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS: JD HEALTH's 2025 Results Beat; Investors Should Focus on 2026 Guidance
Recommend 10 Positive 8 Negative 5 |
||||
|
||||
|
JD HEALTH (06618.HK) has announced its full-year results for the period ending December 2025, with revenue growing by 26.3% to RMB73.4 billion and an adjusted net profit hitting RMB6.5 billion, according to a UBS research report. Both revenue and profit exceeded expectations. UBS attributed the YoY increase of 27.4% in JD HEALTH's 4Q25 revenue to seasonal flu demand, and investors should focus on the 2026 guidance. The broker set a target price of HKD78 for JD HEALTH, with a Buy rating. AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
